METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM
Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.
1 . A method of decreasing excessive daytime sleepiness in a human subject, the method comprising:
administering to the subject a dose of gamma-hydroxybutyrate, wherein the administering occurs only once daily; and
co-administering a dose of divalproex sodium, wherein the co-administering results in comparable systemic exposure to gamma-hydroxybutyrate as shown by C max , as compared to when the dose of gamma-hydroxybutyrate is administered alone.
2 . The method of claim 1 , wherein the co-administering achieves a mean C max that is from 80% to 125% of the C max achieved when the dose of gamma-hydroxybutyrate is administered without divalproex sodium.
3 . The method of claim 1 , wherein the co-administering achieves a mean AUC inf that is from 80% to 125% of the AUC inf achieved when the dose of gamma-hydroxybutyrate is administered without divalproex sodium.
4 . The method of claim 1 , wherein the co-administering achieves an AUC ratio range of 0.8 to 1.7 achieved when the dose of gamma-hydroxybutyrate is administered without divalproex sodium.
5 . The method of claim 1 wherein the co-administering results in a T max for divalproex sodium that is bioequivalent to the T max of divalproex sodium when administered alone.
6 . The method of claim 1 , wherein the dose of gamma-hydroxybutyrate comprises an amount of gamma-hydroxybutyrate equivalent to 3.0 g, 4.5 g, 6.0 g, 7.5 g, 9.0 g, 10.5 g or 12 g of sodium oxybate.
7 . The method of claim 1 , wherein the administering occurs at bedtime.
8 . The method of claim 1 , wherein the gamma-hydroxybutyrate comprises the sodium salt of gamma-hydroxybutyric acid, the potassium salt of gamma-hydroxybutyric acid, the magnesium salt of gamma-hydroxybutyric acid, and the calcium salt of gamma-hydroxybutyric acid, and wherein the dose of gamma-hydroxybutyrate comprises an amount of the gamma-hydroxybutyrate equivalent to from 3 g to 6 g of sodium oxybate.
9 . The method of claim 8 , wherein the administering comprises administering a reduced dosage amount of the dose of gamma-hydroxybutyrate relative to a dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering.
10 . The method of claim 9 , wherein the dose of gamma-hydroxybutyrate is reduced by less than 5% relative to the dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering.
11 . The method of claim 9 , wherein the dose of gamma-hydroxybutyrate is reduced by at least 20% relative to the dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering.
12 . The method of claim 1 , wherein the administering comprises administering a dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering, and co-administering comprises administering a dosage amount of the dose of divalproex sodium equivalent to the dosage amount that would be administered to the subject absent co-administration with the dose of gamma-hydroxybutyrate.
13 . The method of claim 1 , wherein the administering comprises administering a reduced dosage amount of the dose of gamma-hydroxybutyrate relative to a dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering, and the co-administering comprises administering a dosage amount of the dose of divalproex sodium equivalent to the dosage amount that would be administered to the subject absent co-administration with gamma-hydroxybutyrate.
14 . The method of claim 13 , wherein the dose of gamma-hydroxybutyrate is reduced by less than 5% relative to the dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering.
15 . The method of claim 13 , wherein the dose of gamma-hydroxybutyrate is reduced by at least 20% relative to the dosage amount of the dose of gamma-hydroxybutyrate that would be administered to the subject absent the co-administering.
16 . The method of claim 1 , wherein the dose of gamma-hydroxybutyrate comprises an immediate-release portion and a modified-release portion, each of which comprises at least some of the gamma-hydroxybutyrate.
17 . A method of decreasing excessive daytime sleepiness in a human subject, the method comprising:
orally administering a single nighttime daily dose to the human subject,
wherein the single nighttime daily dose comprises a first salt of gamma-hydroxybutyric acid and a second salt of gamma-hydroxybutyric acid,
wherein the first salt is selected from the group consisting of a sodium salt of gamma-hydroxybutyric acid, a calcium salt of gamma-hydroxybutyric acid, a potassium salt of gamma-hydroxybutyric acid, and a magnesium salt of gamma-hydroxybutyric acid,
wherein the second salt differs from the first salt and is selected from the group consisting of a sodium salt of gamma-hydroxybutyric acid, a calcium salt of gamma-hydroxybutyric acid, a potassium salt of gamma-hydroxybutyric acid, and a magnesium salt of gamma-hydroxybutyric acid, and
wherein the orally administering occurs only once nightly; and
co-administering divalproex sodium.
18 . The method of claim 17 , wherein the human subject achieves a decrease in excessive daytime sleepiness when measured by the Epworth Sleepiness Scale (ESS), a decrease in excessive daytime sleepiness when measured by the Maintenance of Wakefulness Test, an improved Clinical Global Impression (CGI) rating of sleepiness, or a decrease in weekly cataplexy attacks.
19 . A method of decreasing excessive daytime sleepiness in a human subject, the method comprising:
initiating a starting dosage, wherein the initiating comprises orally administering a single nighttime daily dose to the human subject,
wherein the single nighttime daily dose comprises a sodium salt of gamma-hydroxybutyric acid, a calcium salt of gamma-hydroxybutyric acid, a potassium salt of gamma-hydroxybutyric acid, and a magnesium salt of gamma-hydroxybutyric acid, w
herein the orally administering occurs only once nightly; and
co-administering divalproex sodium.
20 . The method of claim 19 , wherein the human subject achieves a decrease in excessive daytime sleepiness when measured by the Epworth Sleepiness Scale (ESS), a decrease in excessive daytime sleepiness when measured by the Maintenance of Wakefulness Test, an improved Clinical Global Impression (CGI) rating of sleepiness, or a decrease in weekly cataplexy attacks.